| 摘要 |
This invention is based, at least in part, on the finding that certain microRNAs (miRNAs) are expressed at higher or lower levels in circulating exosonies or peripheral blood of subjects with hematological malignancies compared to the level of expression in subjects who do not have the hematological malignancy. In addition, this invention is based, at least in part, on the finding that certain miRNAs are differentially expressed at different stages of a hematological malignancy permitting identification of the stage of the hematological malignancy in a subject. The differential expression of miRNAs at different stages of a hematological malignancy also permits determination of the effectiveness of treatments administered to a subject at the particular stage of the hematological malignancy. |
| 主权项 |
1. A method of determining the likelihood of a subject having a hematological malignancy, the method comprising:
a) identifying a subject who is suspected of having a hematological malignancy; b) obtaining a biological sample from the subject; c) determining from the biological sample that
(i) the subject has an altered level of one or more micro RNAs (miRs) compared to a control level, or(ii) the subject does not have an altered level of expression of the miRs compared to the control level,wherein the one or more miRs are selected from the group consisting of miR-450a, miR-30e, miR-125a, miR-300, miR-30d, miR-144, miR-451a, miR-107, miR-125b, miR-143, miR-720, miR-155, miR-185, miR-150, miR-98, miR-374b, miR-28, miR-92a, miR-32, miR-548a, miR-939, miR-99a, miR-345, miR-125a, miR-587, miR-323b, miR-let-7g, miR-223, miR-150, miR-15a, miR-19b, miR-21, miR-let-7b, and miR-let-7c; and d) based on determination (c)(i), identifying the subject as likely to have the hematological malignancy, and
based on determination (c)(ii), identifying the subject as not likely to have the hematological malignancy. |
